Children, especially those under five years old, are highly vulnerable to severe malaria, which can lead to serious complications and death if not treated promptly. Artesunate is recommended by the World Health Organization (WHO) for the treatment of severe malaria in children due to its superior efficacy and safety profile compared to other antimalarial drugs such as quinine.
